QUINAZOLINONE, QUINOLONE AND RELATED ANALOGUES AS SIRTUIN MODULATORS Russian patent published in 2014 - IPC C07D401/12 C07D405/12 C07D413/12 C07D417/12 C07D239/91 C07D417/14 C07D401/14 C07D453/02 C07D403/12 C07D403/14 A61K31/5377 A61K31/4375 A61K31/439 A61K31/4709 A61K31/497 A61K31/506 A61K31/517 A61P3/10 A61P5/50 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of structural formula or a salt thereof, where each of Z¹, Z² and Z³ is independently selected from N and C(R⁹), where not more than one of Z¹, Z² and Z³ is N; each R⁹ is hydrogen; and is a second chemical bond between either W² and C(R¹²), or W¹ and C(R¹²); W¹ is -N=, and W²(R¹⁴) is selected from -N(R¹⁴)- and -C(R¹⁴)=, such that when W¹ is -N=, W²(R¹⁴) is -N(R¹⁴)- and is a second chemical bond between W¹ and C(R¹²); R¹¹ is selected from phenyl and a heterocycle which is selected from a saturated or aromatic 5-6-member monocyclic ring, which contains one or two or three heteroatoms selected from N, O and S, or an 8-member bicyclic ring which contains one or more heteroatoms selected from N, O and S, where R¹¹ is optionally substituted with one or two substitutes independently selected from halogen, C₁-C₄ alkyl, =O, -O-R¹³, -(C₁-C₄ alkyl)-N(R¹³)(R¹³), -N(R¹³)(R¹³), where each R¹³ is independently selected from -C₁-C₄alkyl; or two R¹³ together with a nitrogen atom to which they are bonded form a 5-6-member saturated heterocycle, optionally containing an additional heteroatom selected from NH and O, where if R¹³ is an alkyl, the alkyl is optionally substituted with one or more substitutes selected from -OH, fluorine, and if two R¹³ together with the nitrogen atom to which they are bonded form a 5-6-member saturated heterocycle, the saturated heterocycle is optionally substituted on any carbon atom with fluorine; R¹² is selected from phenyl, a 4-6-member monocyclic saturated ring and a heterocycle, which is selected from an aromatic 5-6-member monocyclic ring which contains one or two heteroatoms selected from N and S, where R¹² is optionally substituted with one or more substitutes independently selected from halogen, -C≡N, C₁-C₄ alkyl, C₁-C₂ fluorine-substituted alkyl, -O-R¹³, -S(O)₂-R¹³, -(C₁-C₄ alkyl)-N(R¹³)(R¹³), -N(R¹³)(R¹³); R¹⁴ is selected from hydrogen, C₁-C₄ alkyl, C₁-C₄ fluorine-substituted alkyl, C₁-C₄ alkyl-N(R¹³)(R¹³), C₁-C₄ alkyl-C(O)-N(R¹³)(R¹³); and X¹ is selected from -NH-C(=O)-†, -C(=O)-NH-†, -NH-S(=O)₂-†, where † denotes the point where X¹ is bonded to R¹¹. The invention also relates to a pharmaceutical composition having sirtuin modelling activity based on said compounds.

EFFECT: obtaining novel compounds and a pharmaceutical composition based on said compounds, which can be used in medicine to treat a subject suffering from or susceptible to insulin resistance, metabolic syndrome, diabetes or complications thereof.

18 cl, 2 tbl, 52 ex